Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and cns penetrable BACE inhibitors for the treatment of alzheimers disease

Journal of Medicinal Chemistry

Volumn 55, Issue 21, 2012, Pages 9156-9169

  Huang, Hongbing ^a   La, Daniel S ^a   Cheng, Alan C ^a   Whittington, Douglas A ^a   Patel, Vinod F ^a   Chen, Kui ^a   Dineen, Thomas A ^a   Epstein, Oleg ^a   Graceffa, Russell ^a   Hickman, Dean ^a   Kiang, Y H ^a   Louie, Steven ^a   Luo, Yi ^a   Wahl, Robert C ^a   Wen, Paul H ^a   Wood, Stephen ^a   Fremeau, Robert T ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOOXAZOLINE XANTHENE DERIVATIVE; AMYLOID BETA PROTEIN[1-40]; BETA SECRETASE INHIBITOR; UNCLASSIFIED DRUG; XANTHENE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; NONHUMAN; RAT; REACTION ANALYSIS; SINGLE DRUG DOSE; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OXAZOLES; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHENES;

EID: 84868517170     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300598e     Document Type: Article

References (75)

1. Cummings, J. L. Biomarkers in Alzheimers disease drug development Alzheimer's Dementia 2011, 7 (3) e13-e44
2. Cummings, J. L. Alzheimers disease N. Engl. J. Med. 2004, 351 (1) 56-67
3. Citron, M. Alzheimers disease: strategies for disease modification Nat. Rev. Drug Discovery 2010, 9 (5) 387-98
4. Jakob-Roetne, R.; Jacobsen, H. Alzheimers disease: from pathology to therapeutic approaches Angew Chem., Int. Ed. 2009, 48 (17) 3030-3059
5. Medina, M. Recent developments in tau-based therapeutics for neurodegenerative diseases Recent Pat. CNS Drug Discovery 2011, 6 (1) 20-30
6. Mattson, M. P. Pathways towards and away from Alzheimers disease Nature 2004, 430 (7000) 631-639
7. Nussbaum, R. L.; Ellis, C. E. Alzheimers disease and Parkinsons disease N. Engl. J. Med. 2003, 348 (14) 1356-1364
8. Selkoe, D. J. Translating cell biology into therapeutic advances in Alzheimers disease Nature 1999, 399 (6738 Suppl.) A23-A31
9. Checler, F.; Turner, A. J. Journal of Neurochemistry special issue on Alzheimers disease: "amyloid cascade hypothesis-20 years on" J. Neurochem. 2012, 120 (Suppl. 1) iii-iv
10. Armstrong, R. A. The pathogenesis of Alzheimers disease: a reevaluation of the "amyloid cascade hypothesis" Int. J. Alzheimer's Dis. 2011, 2011, 630865
11. Cummings, J. Alzheimers disease: clinical trials and the amyloid hypothesis Ann. Acad. Med. Singapore 2011, 40 (7) 304-303
12. Sinha, S.; Lieberburg, I. Cellular mechanisms of beta-amyloid production and secretion Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (20) 11049-11053
13. Wang, Z.; Yang, L.; Zheng, H. Role of APP and Abeta in synaptic physiology Curr. Alzheimer Res. 2012, 9 (2) 217-226
14. Chasseigneaux, S.; Allinquant, B. Functions of Abeta, sAPPalpha and sAPPbeta: similarities and differences J. Neurochem. 2012, 120 (Suppl. 1) 99-108
15. Guo, Q.; Li, H.; Gaddam, S. S.; Justice, N. J.; Robertson, C. S.; Zheng, H. Amyloid precursor protein revisited: neuron-specific expression and highly stable nature of soluble derivatives J. Biol. Chem. 2012, 287 (4) 2437-2445
16. Farah, M. H.; Pan, B. H.; Hoffman, P. N.; Ferraris, D.; Tsukamoto, T.; Nguyen, T.; Wong, P. C.; Price, D. L.; Slusher, B. S.; Griffin, J. W. Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system J. Neurosci. 2011, 31 (15) 5744-5754
17. Nikolaev, A.; McLaughlin, T.; OLeary, D. D.; Tessier-Lavigne, M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases Nature 2009, 457 (7232) 981-989
18. Cho, J. E.; Kim, J. R. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimers disease Recent Pat. CNS Drug Discovery 2011, 6 (3) 222-233
19. Ganjei, J. K. Targeting amyloid precursor protein secretases: Alzheimers disease and beyond Drug News Perspect. 2010, 23 (9) 573-584
20. Silvestri, R. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimers disease Med. Res. Rev. 2009, 29 (2) 295-338
21. Albert, J. S. Progress in the development of beta-secretase inhibitors for Alzheimers disease Prog. Med. Chem. 2009, 48, 133-161
22. Guo, T.; Hobbs, D. W. Development of BACE1 inhibitors for Alzheimers disease Curr. Med. Chem. 2006, 13 (15) 1811-1829
23. Luo, Y.; Bolon, B.; Kahn, S.; Bennett, B. D.; Babu-Khan, S.; Denis, P.; Fan, W.; Kha, H.; Zhang, J.; Gong, Y.; Martin, L.; Louis, J. C.; Yan, Q.; Richards, W. G.; Citron, M.; Vassar, R. Mice deficient in BACE1, the Alzheimers beta-secretase, have normal phenotype and abolished beta-amyloid generation Nat. Neurosci. 2001, 4 (3) 231-232
24. Cai, H.; Wang, Y.; McCarthy, D.; Wen, H.; Borchelt, D. R.; Price, D. L.; Wong, P. C. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons Nat. Neurosci. 2001, 4 (3) 233-234
25. Roberds, S. L.; Anderson, J.; Basi, G.; Bienkowski, M. J.; Branstetter, D. G.; Chen, K. S.; Freedman, S. B.; Frigon, N. L.; Games, D.; Hu, K.; Johnson-Wood, K.; Kappenman, K. E.; Kawabe, T. T.; Kola, I.; Kuehn, R.; Lee, M.; Liu, W.; Motter, R.; Nichols, N. F.; Power, M.; Robertson, D. W.; Schenk, D.; Schoor, M.; Shopp, G. M.; Shuck, M. E.; Sinha, S.; Svensson, K. A.; Tatsuno, G.; Tintrup, H.; Wijsman, J.; Wright, S.; McConlogue, L. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimers disease therapeutics Hum. Mol. Genet. 2001, 10 (12) 1317-1324
26. Ghosh, A. K.; Brindisi, M.; Tang, J. Developing beta-secretase inhibitors for treatment of Alzheimers disease J. Neurochem. 2012, 120 (Suppl. 1) 71-83
27. Safety Study of CTS21166 To Treat Alzheimer Disease. http:// clinicaltrials.gov/ct2/show/NCT00621010 (accessed April 2012).
28. Drahl, C. Beta Testing Chem. Eng. News 2010, 88, 14
29. Huang, X. P.; Chang, W. P.; Koelsch, G.; Turner, R. T., 3rd; Lupu, F.; Tang, J. Internalization of exogenously added memapsin 2 (beta-secretase) ectodomain by cells is mediated by amyloid precursor protein J. Biol. Chem. 2004, 279 (36) 37886-37894
30. He, X.; Cooley, K.; Chung, C. H.; Dashti, N.; Tang, J. Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production J. Neurosci. 2007, 27 (15) 4052-4060
31. Rajendran, L.; Schneider, A.; Schlechtingen, G.; Weidlich, S.; Ries, J.; Braxmeier, T.; Schwille, P.; Schulz, J. B.; Schroeder, C.; Simons, M.; Jennings, G.; Knolker, H. J.; Simons, K. Efficient inhibition of the Alzheimers disease beta-secretase by membrane targeting Science 2008, 320 (5875) 520-523
32. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J. C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. Beta-secretase cleavage of Alzheimers amyloid precursor protein by the transmembrane aspartic protease BACE Science 1999, 286 (5440) 735-741
33. Yan, R.; Bienkowski, M. J.; Shuck, M. E.; Miao, H.; Tory, M. C.; Pauley, A. M.; Brashier, J. R.; Stratman, N. C.; Mathews, W. R.; Buhl, A. E.; Carter, D. B.; Tomasselli, A. G.; Parodi, L. A.; Heinrikson, R. L.; Gurney, M. E. Membrane-anchored aspartyl protease with Alzheimers disease beta-secretase activity Nature 1999, 402 (6761) 533-537
34. Sinha, S.; Anderson, J. P.; Barbour, R.; Basi, G. S.; Caccavello, R.; Davis, D.; Doan, M.; Dovey, H. F.; Frigon, N.; Hong, J.; Jacobson-Croak, K.; Jewett, N.; Keim, P.; Knops, J.; Lieberburg, I.; Power, M.; Tan, H.; Tatsuno, G.; Tung, J.; Schenk, D.; Seubert, P.; Suomensaari, S. M.; Wang, S.; Walker, D.; Zhao, J.; McConlogue, L.; John, V. Purification and cloning of amyloid precursor protein beta-secretase from human brain Nature 1999, 402 (6761) 537-540
35. Stachel, S. J. Progress toward the development of a viable BACE inhibitor Drug Dev. Res. 2009, 70, 101-110
36. Cole, D. C.; Manas, E. S.; Stock, J. R.; Condon, J. S.; Jennings, L. D.; Aulabaugh, A.; Chopra, R.; Cowling, R.; Ellingboe, J. W.; Fan, K. Y.; Harrison, B. L.; Hu, Y.; Jacobsen, S.; Jin, G.; Lin, L.; Lovering, F. E.; Malamas, M. S.; Stahl, M. L.; Strand, J.; Sukhdeo, M. N.; Svenson, K.; Turner, M. J.; Wagner, E.; Wu, J.; Zhou, P.; Bard, J. Acylguanidines as small-molecule beta-secretase inhibitors J. Med. Chem. 2006, 49 (21) 6158-6161
37. Edwards, P. D.; Albert, J. S.; Sylvester, M.; Aharony, D.; Andisik, D.; Callaghan, O.; Campbell, J. B.; Carr, R. A.; Chessari, G.; Congreve, M.; Frederickson, M.; Folmer, R. H.; Geschwindner, S.; Koether, G.; Kolmodin, K.; Krumrine, J.; Mauger, R. C.; Murray, C. W.; Olsson, L. L.; Patel, S.; Spear, N.; Tian, G. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency J. Med. Chem. 2007, 50 (24) 5912-5925
38. Congreve, M.; Aharony, D.; Albert, J.; Callaghan, O.; Campbell, J.; Carr, R. A.; Chessari, G.; Cowan, S.; Edwards, P. D.; Frederickson, M.; McMenamin, R.; Murray, C. W.; Patel, S.; Wallis, N. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase J. Med. Chem. 2007, 50 (6) 1124-1132
39. Baxter, E. W.; Conway, K. A.; Kennis, L.; Bischoff, F.; Mercken, M. H.; Winter, H. L.; Reynolds, C. H.; Tounge, B. A.; Luo, C.; Scott, M. K.; Huang, Y.; Braeken, M.; Pieters, S. M.; Berthelot, D. J.; Masure, S.; Bruinzeel, W. D.; Jordan, A. D.; Parker, M. H.; Boyd, R. E.; Qu, J.; Alexander, R. S.; Brenneman, D. E.; Reitz, A. B. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): use of structure based design to convert a micromolar hit into a nanomolar lead J. Med. Chem. 2007, 50 (18) 4261-4264
40. Malamas, M. S.; Erdei, J.; Gunawan, I.; Turner, J.; Hu, Y.; Wagner, E.; Fan, K.; Chopra, R.; Olland, A.; Bard, J.; Jacobsen, S.; Magolda, R. L.; Pangalos, M.; Robichaud, A. J. Design and synthesis of 5,5′-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors J. Med. Chem. 2010, 53 (3) 1146-1158
41. Cole, D. C.; Bursavich, M. G. Nonpeptide BACE 1 Inhibitors: Design and Synthesis. In Methods and Principles in Medicinal Chemistry; Ghosh, A. K., Ed.; Wiley-VCH: Weinheim, Germany, 2010; Vol. 45, pp 481-509.
42. The Asp binding moiety would act as the pharmocaphore and therefore be implemented into every compound henceforth. Thus, this portion required the heaviest physiochemical design restrictions. Wager, T. T.; Villalobos, A.; Verhoest, P. R.; Hou, X.; Shaffer, C. L. Strategies to optimize the brain availability of central nervous system drug candidates Expert Opin. Drug Discovery 2011, 6, 371-381
43. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships J. Med. Chem. 2006, 49 (26) 7559-7583
44. a values were calculated using the following: ACD LogD Suite, version 10; Advanced Chemistry Development Inc.: Toronto, Canada.
45. Rajamani, R.; Reynolds, C. H. Modeling the protonation states of the catalytic aspartates in beta-secretase J. Med. Chem. 2004, 47 (21) 5159-5166
46. Sidera, C.; Liu, C.; Austen, B. Pro-domain removal in ASP-2 and the cleavage of the amyloid precursor are influenced by pH BMC Biochem. 2002, 3, 25
47. Dominguez, J. L.; Christopeit, T.; Villaverde, M. C.; Gossas, T.; Otero, J. M.; Nystrom, S.; Baraznenok, V.; Lindstrom, E.; Danielson, U. H.; Sussman, F. Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1 Biochemistry 2010, 49 (34) 7255-7263
48. Stachel, S. J.; Coburn, C. A.; Rush, D.; Jones, K. L.; Zhu, H.; Rajapakse, H.; Graham, S. L.; Simon, A.; Katharine Holloway, M.; Allison, T. J.; Munshi, S. K.; Espeseth, A. S.; Zuck, P.; Colussi, D.; Wolfe, A.; Pietrak, B. L.; Lai, M. T.; Vacca, J. P. Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1 Bioorg. Med. Chem. Lett. 2009, 19 (11) 2977-2980
49. Rajapakse, H. A.; Nantermet, P. G.; Selnick, H. G.; Barrow, J. C.; McGaughey, G. B.; Munshi, S.; Lindsley, S. R.; Young, M. B.; Ngo, P. L.; Holloway, M. K.; Lai, M. T.; Espeseth, A. S.; Shi, X. P.; Colussi, D.; Pietrak, B.; Crouthamel, M. C.; Tugusheva, K.; Huang, Q.; Xu, M.; Simon, A. J.; Kuo, L.; Hazuda, D. J.; Graham, S.; Vacca, J. P. SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition Bioorg. Med. Chem. Lett. 2010, 20 (6) 1885-1889
50. Reynolds, D. P.; Lanevskij, K.; Japertas, P.; Didziapetris, R.; Petrauskas, A. Ionization-specific analysis of human intestinal absorption J. Pharm. Sci. 2009, 98 (11) 4039-4054
51. Kotthaus, J.; Hungeling, H.; Reeh, C.; Schade, D.; Wein, S.; Wolffram, S.; Clement, B. Synthesis and biological evaluation of l -valine-amidoximeesters as double prodrugs of amidines Bioorg. Med. Chem. 2011, 19 (6) 1907-1914
52. Peterlin-Masic, L.; Cesar, J.; Zega, A. Metabolism-directed optimisation of antithrombotics: the prodrug principle Curr. Pharm. Des 2006, 12 (1) 73-91
53. Kaller, M. R.; Harried, S. S.; Albercht, B.; Amarante, P.; Babu-Khan, S.; Bartberger, M. D.; Brwon, J.; Brown, R.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Graceffa, R.; Hickman, D.; Judd, T.; Kriemen, C.; La, D.; Li, V.; Lopez, P.; Luo, Y.; Masse, C.; Monenschein, H.; Nguyen, T.; Pennington, L. D.; Miguel, T. S.; Sickmier, E. A.; Wahl, R. C.; Weiss, M. M.; Wen, P. H.; Williamson, T.; Wood, S.; Xue, M.; Yang, B.; Zhang, J.; Patel, V.; Zhong, W.; Hitchcock, S. A potent and orally efficacious, hydroxyethylamine-based inhibitor of β-secretase. ACS Med. Chem. Lett. [Online early access]. DOI: 10.1021/ml3000148. Published Online: April 22, 2012.
54. Ward, J. M.; Gorenstein, N. M.; Tian, J.; Martin, S. F.; Post, C. B. Constraining binding hot spots: NMR and molecular dynamics simulations provide a structural explanation for enthalpy-entropy compensation in SH2-ligand binding J. Am. Chem. Soc. 2010, 132 (32) 11058-11070
55. Schneider, H.-J. In Protein-Ligand Interactions: From Molecular Recognition to Drug Design; Böhm, H.-J.; Schneider, G., Eds; Wiley-VCH: Weinheim, Germany, 2003; pp 21-50.
56. Turner, R. T., 3rd; Koelsch, G.; Hong, L.; Castanheira, P.; Ermolieff, J.; Ghosh, A. K.; Tang, J. Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design Biochemistry 2001, 40 (34) 10001-10006
57. Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C. W.; Yon, J. Apo and inhibitor complex structures of BACE (beta-secretase) J. Mol. Biol. 2004, 343 (2) 407-416
58. Hong, L.; Turner, R. T., 3rd; Koelsch, G.; Shin, D.; Ghosh, A. K.; Tang, J. Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3 Biochemistry 2002, 41 (36) 10963-10967
59. Stachel, S. J.; Coburn, C. A.; Steele, T. G.; Jones, K. G.; Loutzenhiser, E. F.; Gregro, A. R.; Rajapakse, H. A.; Lai, M. T.; Crouthamel, M. C.; Xu, M.; Tugusheva, K.; Lineberger, J. E.; Pietrak, B. L.; Espeseth, A. S.; Shi, X. P.; Chen-Dodson, E.; Holloway, M. K.; Munshi, S.; Simon, A. J.; Kuo, L.; Vacca, J. P. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1) J. Med. Chem. 2004, 47 (26) 6447-6450
60. Coburn, C. A.; Stachel, S. J.; Li, Y. M.; Rush, D. M.; Steele, T. G.; Chen-Dodson, E.; Holloway, M. K.; Xu, M.; Huang, Q.; Lai, M. T.; DiMuzio, J.; Crouthamel, M. C.; Shi, X. P.; Sardana, V.; Chen, Z.; Munshi, S.; Kuo, L.; Makara, G. M.; Annis, D. A.; Tadikonda, P. K.; Nash, H. M.; Vacca, J. P.; Wang, T. Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases J. Med. Chem. 2004, 47 (25) 6117-6119
61. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J. R.; Raevsky, O. A. Estimation of bloo-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors J. Drug Targeting 1998, 6 (2) 151-165
62. Obach, R. S. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol Drug Metab. Dispos. 1997, 25 (12) 1359-1369
63. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Drug Metab. Dispos. 1999, 27 (11) 1350-1359
64. Smith, D. A.; van de Waterbeemd, H.; Walker, D. K. In Pharmacokinetics and Metabolishm in Drug Design; Mannhold, R.; Kubinyi, H.; Folkers, G., Eds; Wiley-VCH: Weinheim, Germany, 2006; pp 165-177.
65. Dineen, T. A.; Weiss, M. M.; Williamson, T.; Acton, P.; Babu-Khan, S.; Bartberger, M. D.; Brown, J.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Dunn, R. T., 2nd; Esmay, J.; Graceffa, R. F.; Harried, S. S.; Hickman, D.; Hitchcock, S. A.; Horne, D. B.; Huang, H.; Imbeah-Ampiah, R.; Judd, T.; Kaller, M. R.; Kreiman, C. R.; La, D. S.; Li, V.; Lopez, P.; Louie, S.; Monenschein, H.; Nguyen, T. T.; Pennington, L. D.; San Miguel, T.; Sickmier, E. A.; Vargas, H. M.; Wahl, R. C.; Wen, P. H.; Whittington, D. A.; Wood, S.; Xue, Q.; Yang, B. H.; Patel, V. F.; Zhong, W. Design and synthesis of potent, orally efficacious hydroxyethylamine derived beta-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J. Med. Chem. [Online early access]. DOI: 10.1021/jm300118s. Published Online: April 18, 2012.
66. Marcoux, J.; Doye, S; Buchwald, S. L. A general copper-catalyzed syntesis of diaryl ethers J. Am. Chem. Soc. 1997, 119, 10539-10540
67. Peterson, D. J. Carbonyl olefination reaction using silyl-substituted organometallic compounds J. Org. Chem. 1968, 33, 780-784
68. Fernandez, J. M. G.; Mellet, C. O.; Adrian, M. A. P.; Mota, J. F. Syntheses and spectral properties of β-iodoureas and 2-amino-4,4-diphenyl- 2-oxazolines J. Heterocycl. Chem. 1991, 28, 777-780
69. Haniu, M.; Denis, P.; Young, Y.; Mendiaz, E. A.; Fuller, J.; Hui, J. O.; Bennett, B. D.; Kahn, S.; Ross, S.; Burgess, T.; Katta, V.; Rogers, G.; Vassar, R.; Citron, M. Characterization of Alzheimers beta-secretase protein BACE. A pepsin family member with unusual properties J. Biol. Chem. 2000, 275 (28) 21099-21106
70. Schinkel, A. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A.; Borst, P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J. Clin. Invest. 1995, 96 (4) 1698-1705
71. Booth-Genthe, C. L.; Louie, S. W.; Carlini, E. J.; Li, B.; Leake, B. F.; Eisenhandler, R.; Hochman, J. H.; Mei, Q.; Kim, R. B.; Rushmore, T. H.; Yamazaki, M. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse J. Pharmacol. Toxicol. Methods 2006, 54 (1) 78-89
72. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 1997, 276, 307-326
73. Navaza, J. AMoRe: an automated package for molecular replacement Acta Crystallogr. A 1994, 50, 157-163
74. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53 (Part 3) 240-255
75. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132